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Background: There is a paucity of data on familial risk of developing esophageal adenocarcinoma, gastric cardia
adenocarcinoma and distal gastric adenocarcinoma from population-based studies.
Methods: A population-based case–control study of newly diagnosed gastroesophageal adenocarcinoma was
conducted in Los Angeles County. This analysis included data of case-patients whom we were able to interview
directly (147 patients with esophageal adenocarcinoma, 182 with gastric cardia adenocarcinoma, and 285 with
distal gastric adenocarcinoma) and 1,309 control participants. Multivariate polytomous logistic regression was used
to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for the three cancer types.
Results: Risk of esophageal adenocarcinoma was positively associated with a family history of prostate cancer
(OR = 2.84; 95% CI = 1.50-5.36) and a family history of hiatal hernia (OR = 2.04; 95% CI = 1.12-3.71). Risk of gastric cardia
adenocarcinoma was strongly associated with a family history of esophageal cancer (OR = 5.18; 95% CI = 1.23-21.79)
and a family history of hiatal hernia (OR = 2.31; 95% CI = 1.37-3.91). Risk of distal gastric adenocarcinoma was positively
associated with a family history of gastric cancer (OR = 2.15; 95% CI = 1.18-3.91), particularly early-onset (before age 50)
gastric cancer (OR = 2.82; 95% CI = 1.11-7.15).
Conclusions: This study provides evidence that family history of hiatal hernia is a risk factor for esophageal
adenocarcinoma and gastric cardia adenocarcinoma and that cancer in specific sites is associated with risk of
esophageal adenocarcinoma, gastric cardia adenocarcinoma, and distal gastric adenocarcinoma. It is important
to determine the extent to which shared environmental and genetic factors explain these familial associations.
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Esophageal and gastric cancers are one of the most com-
mon cancers in the world, with an estimated 482,300 new
esophageal cancer cases and 989,600 new gastric cancer
cases diagnosed in 2008 worldwide. However, incidence
rates at these two cancer sites vary substantially inter-
nationally [1]. In the last few decades, despite the decline
in esophageal squamous cell carcinoma and distal gastric
cancer in most parts of the world [2], incidence rates of
adenocarcinomas of the esophagus (EA) and gastric
cardia (GCA) have been rising rapidly in the Western* Correspondence: annawu@usc.edu
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reproduction in any medium, provided the orcountries, possibly due to the increasing prevalence of
two risk factors, obesity and reflux conditions [3,4]. A
pooled analysis of individual participant data from 12
epidemiological studies worldwide found increasing risk of
both EA and GCA with increasing body mass index (BMI)
and evidence for a synergistic interaction between obesity
and gastroesophageal reflux (GERD) symptoms [3]. Com-
pared with individuals with a BMI <25 kg/m2, individuals
with BMI ≥40 kg/m2 had a >4 fold increase in EA risk
and >3 fold increase in GCA. There are also some reports
of stable or declining incidence of GCA in more recent
years. A 2012 study [5] reported that in the Netherlands,
the incidence for GCA decreased in males but remained
stable in females, changes that are unlikely caused by
improved disease diagnosis or reclassification. In thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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esophageal squamous cell carcinoma [6]. Most EAs are
believed to originate from Barrett’s esophagus [7], which is
strongly associated with gastroesophageal reflux disease
and presence of hiatal hernia. The geographic variations
and temporal changes in the incidence of esophageal and
gastric cancer indicate an important role of environmental
factors in the development of these diseases. There is also
evidence implicating an etiologic role of genetic factors.
Studies have shown higher risk of esophageal and gastric
cancers among close relatives of patients with these dis-
eases [4,8-14]. However, to our knowledge, only one [12]
of these three studies [10-12] that have evaluated the
familial risk of histology- and site-specific subtypes of
esophageal and gastric cancer was a population-based
study. For the present analyses, we utilized data from a
well-characterized population-based case–control study
to assess whether family history of gastrointestinal cancers,
other cancers and gastroesophageal disorders (hiatal
hernia, any ulcer, gastritis, and Barrett’s esophagus) are
associated with risk of EA, GCA, and distal gastric
adenocarcinoma (DGA). Our investigation not only sepa-
rated gastroesophageal adenocarcinoma by anatomical
sites, but also investigated the effect of family history




The details of the study population and design have been
described previously [15-20]. Briefly, case patients eligible
for this study were men and women between the age of
30 and 74 years newly diagnosed with histologically
confirmed, incident EA (International Classification of
Disease for Oncology code [ICD-O] C15.0-C15.9), GCA
(ICD-O code C16.0), or DCA (ICD-O codes C16.1-C16.6
and C16.8-C16.9) diagnosed between 1992 and 1997. They
were identified by the Los Angeles County Cancer Surveil-
lance Program, the population-based cancer registry
covering Los Angeles County, a member of the National
Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program, and the statewide California Can-
cer Registry. Control participants were subjects without a
diagnosis of gastric or esophageal cancer. They were indi-
vidually matched to each case patient on sex, race, age
(±5 years) and neighborhood of residence. A systematic
algorithm based on the address of each case patient was
used to recruit the case’s matched control [17]. To in-
crease the study’s statistical power, we sought two control
participants for each case patient whenever possible.
The study was approved by the Institutional Review
Board of the Keck School of Medicine of the University
of Southern California and all study procedures adhered
to the recommendations of the Declaration of Helsinki.Written informed consent was obtained from each study
participant before interview.
In-person structured interviews were conducted with
participants. Next-of-kin (NOK) were interviewed when
case patients were unable to be interviewed due to death
or illness. Although it was not feasible to blind interviewers
to case (or NOK) or control status, interviewers and study
participants were not aware of the study hypotheses. A
total of 947 case patients were interviewed, representing
77% of the 1230 eligible patients who were approached
(77% for EA, 74% for GA, and 78% for DGA). Among
them, 528 were matched to one control participant, 382
were matched to two or more control participants, and
37 had no eligible control participant identified. For the
current analysis, data from 271 NOK case-patient inter-
views (66 EA, 85 GCA and 120 DGA) were excluded to
reduce misclassification of family history. We also excluded
62 case patients and 47 control participants because of
extreme caloric intake (so the analysis cohort could be as
comparable as possible to those in previous publications
from the same study) or missing information on key
covariates (smoking, body size and others). A total of 614
case patients (147 with EA, 182 with GCA and 285 with
DGA) and 1,309 control participants were included in the
statistical analyses.
Data collection
Cases and their matching controls were interviewed by
the same interviewer in almost all instances. A reference
date was defined as one year before the date of diagnosis
of the case patient; this same reference date was used for
each case patient’s matched control subject(s). A structured
questionnaire designed specifically for this study was
administered during the in-person interview, obtaining
data up to the reference date. The interview queried
demographic information, smoking history, lifetime use
of all types of alcoholic beverages, usual diet, weight at
ages 20 and 40 years and on the reference date (referred
to as current weight), and height. To assess a participant’s
medical history of a list of diseases, we asked if the partici-
pant had any of the conditions diagnosed by a physician
before the reference date. Conditions of the upper gastro-
intestinal tract that were asked included gastric ulcer,
duodenal ulcer, gastritis, hiatal or diaphragmatic hernia,
esophagitis, Barrett’s esophagus, gastresophageal reflux
disease, excess acid, and gastric hyperacidity.
In addition, we asked detailed questions regarding his-
tory of conditions of esophagus and gastrointestinal tract
and history of any cancer among participants’ first-degree
relatives. Specifically, each participant was asked about
the vital status of his/her natural mother and father, the
number of full-brothers and full-sisters, and if any of
these immediate family members was ever diagnosed by a
physician for gastritis, hiatal hernia, Barrett’s esophagus,
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of the non-malignant conditions, participants were then
asked at what age was the relative first diagnosed for the
condition. Age at diagnosis was unknown for 15 partici-
pants’ father, 13 participants’ mother, and 17 participants’
siblings. If the response was yes for cancer, participants
were further asked about the cancer site and age at cancer
diagnosis. Cancer sites were coded according to the Inter-
national Classification of Diseases 9th version (ICD-9) code:
any gastrointestinal (ICD-9: 150–159), esophageal (ICD-9:
150), gastric (ICD-9: 151), colorectal (ICD-9: 153–154),
hepatic (ICD-9: 155), pancreas (ICD-9: 157), lung (ICD-9:
162), breast (ICD-9: 174), bone/skin/connective tissue
(ICD-9: 170–173), oral/upper respiratory organ (ICD-9:
140–149, 160–165), prostate (ICD-9: 185), female repro-
ductive organ (ICD-9: 179–184), lymphatic/hematopoietic
(ICD-9: 200, 208) cancer, and cancer of unknown primary
site (ICD-9: 199). Numbers of other cancers reported in
these relatives were insufficient for reliable analyses. If
the participant did not have any siblings, only the parents’
history was counted.
Statistical analysis
A participant was classified as having a family history of
a condition if they reported at least one first-degree rela-
tive (biological parent or sibling) with the condition and
as having a family history of an early-onset condition if
they reported at least one first-degree relative with the
condition who was diagnosed before age 50 years. A
family history of cancer with unknown age at diagnosis
was treated as a family history of late-onset cancer, given
that most cancers are diagnosed after age 50. Results
were essentially unchanged with or without including
subjects with a family history of cancer of unknown age
at diagnosis.
Odds ratios (OR) and corresponding 95% confidence
intervals (CI) were estimated for associations of family
history with risk of EA, GCA, and DGA. To maximize
our statistical power, we report results from polytomous
logistic regression with adjustment for the matching var-
iables [19] including age (≤49, 50–59, 60–69, ≥70 years),
sex (male/female) and race (non-Hispanic white, African
American, Hispanic, Asian). We previously showed [19]
that this approach provided more precise estimates of
the ORs while the magnitude of the estimated ORs was
consistent with those obtained in separate conditional
logistic regression analyses that preserved the original
case–control match within each cancer site. Given that
the causal factors for esophageal adenocarcinoma is not
entirely known, we chose to adjust for all common risk
factors that were suspected to be associated with both
gastroesophageal adenocarcinomas and family history
of cancer or gastroesophageal disorders: birth place
(US born, non-US born), level of education (<highschool, high school, some college, college graduate or
higher), cigarette smoking status (never, former, and
current smoker), body mass index (BMI) at reference
age (in quartiles: ≤23, >23-25, >25- ≤ 28, >28 in males,
and ≤22, >22-25, >25- ≤ 28.25, >28.25 in females), and
history of diabetes were also included as covariates in
the analyses. BMI was categorized using sex-specific
quartiles rather than the World Health Organization
classification to avoid sparse data for some categories.
Personal history of other malignancies was also included
as a covariate when analyzing the effect of family history
of cancer. Additional adjustment for fiber intake had
minimal effect on the summary estimates so it was not
included in the final model.
Significance of the interaction between family and per-
sonal history of hiatal hernia was evaluated using one
degree of freedom likelihood ratio test of a product term
between the two variables. We conducted these analyses
separately for each type of cancer using unconditional
logistic regression.
All reported P values are two-sided. All statistical analyses
were performed using the SAS 9.2 statistical software (SAS
Institute Inc., Cary, NC).
Results
Demographic characteristics of the cases and controls
have been described in detail previously [19]. Control
subjects who reported a family history of any cancers
were more likely to be older, US born, and non-Hispanic
white than those without a family history of any cancer,
but those with and without a family history did not differ
with regard to gender, level of education, cigarette smok-
ing status, BMI, history of diabetes or reflux symptoms
(Table 1). In contrast, control subjects who reported a
family history of gastroesophageal disorders (hiatal hernia,
any ulcer, gastritis, and Barrett’s esophagus) were more
likely to be younger, female, better educated, and have a
personal history of reflux symptoms than controls without
a family history of gastroesophageal disorders, but were
not different in race/ethnicity, place of birth, cigarette
smoking status, BMI and history of diabetes.
Table 2 presents the risk of the three cancer types in
relation to family history of cancer among first degree
relatives, with adjustment for matching variables (age, sex,
and race) as well as other risk factors of these adenocar-
cinoma identified in our previous investigations. Results
adjusted for matching factors only are also presented in
Additional file 1: Table S1 for comparison. Family history
of cancer was unknown for 17 participants (5 cases and 12
controls). There was essentially no subject with partially
unknown family history of cancer. Risk of EA was posi-
tively associated with a family history of prostate cancer
(OR = 2.84; 95% CI = 1.50-5.36). Risk of EA was also in-
versely associated with family history of breast cancer
Table 1 Family history of cancer and gastroesophageal disorders by demographic and lifestyle characteristics among
control subjects
Family history of any cancer Family history of gastroesophageal disorders
N (row percent) No Yes Pa No Yes Pa
Age 0.005 <0.001
≤49 161 (58.8%) 113 (41.2%) 169 (61.7%) 105 (38.3%)
50-59 174 (52.6%) 157 (47.4%) 217 (65.8%) 113 (34.2%)
60-69 215 (48.3%) 230 (51.7%) 337 (76.8%) 102 (23.2%)
≥70 118 (47.8%) 129 (52.2%) 196 (79.7%) 50 (20.3%)
Gender 0.70 0.003
Male 499 (51.8%) 464 (48.2%) 703 (73.6%) 252 (26.4%)
Female 169 (50.6%) 165 (49.4%) 216 (64.7%) 118 (35.3%)
Race <0.001 0.19
Non-Hispanic white 382 (46.8%) 434 (53.2%) 590 (72.6%) 223 (27.4%)
African American 44 (51.2%) 42 (48.8%) 64 (76.2%) 20 (23.8%)
Hispanics 174 (61.7%) 108 (38.3%) 187 (66.6%) 94 (33.4%)
Asian American 68 (60.2%) 45 (39.8%) 78 (70.3%) 33 (29.7%)
Country of birth <0.001 0.67
U.S. 463 (47.4%) 513 (52.6%) 689 (71.0%) 282 (29.0%)
Other countries 205 (63.9%) 116 (36.1%) 230 (72.3%) 88 (27.7%)
Education 0.28 0.016
<High school 134 (58.8%) 94 (41.2%) 170 (75.6%) 55 (24.4%)
High school 116 (47.5%) 128 (52.5%) 181 (74.8%) 61 (25.2%)
Some college 184 (49.1%) 191 (50.9%) 263 (70.5%) 110 (29.5%)
College graduate or higher 234 (52.0%) 216 (48.0%) 305 (67.9%) 144 (32.1%)
Cigarette smoking status 0.70 0.74
Never smokers 269 (52.2%) 246 (47.8%) 362 (70.8%) 149 (29.2%)
Former smokers 291 (51.0%) 279 (49.0%) 412 (72.8%) 154 (27.2%)
Current smokers 108 (50.9%) 104 (49.1%) 145 (68.4%) 67 (31.6%)
Body mass index (BMI)b 0.60 0.60
Quartile1 207 (57.8%) 171 (45.2%) 266 (70.9%) 109 (29.1%)
Quartile 2 158 (48.0%) 171 (52.0%) 236 (72.2%) 91 (27.8%)
Quartile 3 150 (50.3%) 148 (49.7%) 219 (74.0%) 77 (26.0%)
Quartile 4 153 (52.4%) 139 (47.6%) 198 (68.0%) 93 (32.0%)
Diabetes 0.42 0.91
No 616 (51.8%) 572 (48.2%) 841 (71.2%) 340 (28.8%)
Yes 52 (47.7%) 57 (52.3%) 78 (72.2%) 30 (27.8%)
Personal history of reflux symptoms 0.33 0.026
No 582 (52.1%) 536 (47.9%) 804 (72.4%) 306 (27.6%)
Yes 86 (48.0%) 93 (52.0%) 115 (64.2%) 64 (35.8%)
aP values were estimated using Fisher’s exact test for binary variables, Mantel-Haenszel Chi-Square test for ordinal multi-level variables, and Chi-square test for
nominal multi-level variables.
bQuartile cut points for current BMI are ≤23, >23-25, >25- ≤ 28, >28 kg/m2 for males, and ≤22, >22-25, >25- ≤ 28.25, >28.25 kg/m2 for females.
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this OR estimate did not exclude 1.0. Risk of GCA was
positively associated with a family history of esophageal
cancer (OR = 5.18; 95% CI = 1.23-21.79) but was notassociated with family history of other gastrointestinal
cancers. There was no association between family history
of any non-gastrointestinal cancer and GCA risk. Risk of
DGA was positively associated with a family history of any
Table 2 Family history of cancer and risk of esophageal and gastric adenocarcinoma
History of cancer among
first degree relatives
EA GCA DGA
Controls Cases OR (95% CI)a Pa Cases OR (95% CI)a Pa Cases OR (95% CI)a Pa
Any cancer
No 668 68 1.00 (ref) 90 1.00 (ref) 160 1.00 (ref)
Yes 629 78 1.02 (0.68-1.54) 0.92 91 1.04 (0.71-1.53) 0.83 122 0.83 (0.60-1.15) 0.27
Late-onset 481 58 0.96 (0.62-1.49) 0.85 63 0.96 (0.63-1.46) 0.84 89 0.81 (0.56-1.16) 0.25
Early-onset 148 20 1.24 (0.66-2.35) 0.50 28 1.33 (0.74-2.38) 0.34 33 0.90 (0.54-1.48) 0.67
Gastrointestinal cancer
Any gastrointestinal cancerb
No 1101 125 1.00 (ref) 148 1.00 (ref) 226 1.00 (ref)
Yes 196 21 0.87 (0.48-1.59) 0.66 33 1.19 (0.71-1.97) 0.51 56 1.45 (0.95-2.23) 0.087
Late-onset 153 16 0.85 (0.44-1.65) 0.63 26 1.23 (0.70-2.14) 0.47 40 1.31 (0.80-2.16) 0.28
Early-onset 43 5 0.98 (0.29-3.33) 0.97 7 1.04 (0.36-3.02) 0.95 16 1.84 (0.90-3.78) 0.095
Esophageal cancer
No 1290 145 1.00 (ref) 176 1.00 (ref) 280 1.00 (ref)
Yes 7 1 - - 5 5.18 (1.23-21.79) 0.025 2 - -
Gastric cancer
No 1241 141 1.00 (ref) 171 1.00 (ref) 260 1.00 (ref)
Yes 56 5 0.92 (0.32-2.65) 0.87 10 1.57 (0.72-3.45) 0.26 22 2.15 (1.18-3.91) 0.012
Colorectal cancer
No 1222 138 1.00 (ref) 171 1.00 (ref) 260 1.00 (ref)
Yes 75 8 0.94 (0.39-2.27) 0.89 10 0.70 (0.27-1.79) 0.46 22 1.21 (0.61-2.39) 0.59
Liver cancer
No 1267 139 1.00 (ref) 179 1.00 (ref) 276 1.00 (ref)
Yes 30 7 1.94 (0.64-5.83) 0.24 2 - - 6 0.51 (0.13-2.01) 0.34
Pancreatic cancer
No 1275 145 1.00 (ref) 176 1.00 (ref) 276 1.00 (ref)
Yes 22 1 - - 5 1.55 (0.44-5.43) 0.49 6 2.17 (0.72-6.51) 0.17
Non-gastrointestinal cancer
Lung cancer
No 1202 132 1.00 (ref) 164 1.00 (ref) 267 1.00 (ref)
Yes 95 14 1.03 (0.48-2.24) 0.93 17 0.92 (0.43-1.98) 0.84 15 1.05 (0.52-2.11) 0.90
Upper respiratory organ cancer
No 1172 128 1.00 (ref) 157 1.00 (ref) 260 1.00 (ref)
Yes 125 18 0.98 (0.50-1.93) 0.96 24 1.22 (0.67-2.20) 0.51 22 1.02 (0.57-1.85) 0.94
Skin/bone/connective tissue cancer
No 1225 141 1.00 (ref) 174 1.00 (ref) 272 1.00 (ref)
Yes 72 5 0.61 (0.21-1.74) 0.35 7 0.44 (0.14-1.46) 0.18 10 1.06 (0.40-2.79) 0.90
Lymphatic/hematopoietic cancer
No 1256 141 1.00 (ref) 179 1.00 (ref) 272 1.00 (ref)
Yes 41 5 1.49 (0.56-3.96) 0.43 2 - - 10 0.90 (0.32-2.55) 0.84
Prostate cancer
No 1224 130 1.00 (ref) 170 1.00 (ref) 272 1.00 (ref)
Yes 73 16 2.84 (1.50-5.36) 0.001 11 1.45 (0.70-3.01) 0.32 10 0.44 (0.17-1.16) 0.10
Jiang et al. BMC Cancer 2014, 14:60 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/60
Table 2 Family history of cancer and risk of esophageal and gastric adenocarcinoma (Continued)
Breast cancer
No 1168 137 1.00 (ref) 167 1.00 (ref) 258 1.00 (ref)
Yes 129 9 0.60 (0.28-1.28) 0.19 14 0.68 (0.33-1.40) 0.30 24 0.78 (0.42-1.45) 0.44
Female reproductive organ cancer
No 1228 132 1.00 (ref) 167 1.00 (ref) 263 1.00 (ref)
Yes 67 14 1.59 (0.72-3.51) 0.25 13 1.56 (0.74-3.27) 0.24 17 1.02 (0.52-2.02) 0.94
Unknown primary site
No 1234 139 1.00 (ref) 176 1.00 (ref) 270 1.00 (ref)
Yes 63 7 0.76 (0.29-1.99) 0.58 5 0.54 (0.19-1.54) 0.25 12 0.80 (0.38-1.66) 0.55
Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardiac adenocarcinoma; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval.
aResults were estimated from multivariate polytomous logistic regression, with adjustment for age, sex, race, education, birth place, cigarette smoking status, body
mass index, history of diabetes, and history of other malignancies. History of cancer among first degree relatives was unknown for 17 participants.
bGastrointestinal cancer includes malignant neoplasm of the gastrointestinal tract, including esophagus, stomach, small intestine, colon, rectum, rectosigmoid
junction, anus, liver, gallbladder, intrahepatic and extrahepatic bile ducts, pancreas, and other and ill-defined sites within the digestive organs and peritoneum.
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though the 95% CI for this OR estimate did not exclude
1.0. This increase in risk seemed to be more pronounced
among those with a family history of early-onset (before
age 50 years) gastrointestinal cancer (OR = 1.84; 95% CI =
0.90-3.78) than among those whose family members had
later-onset of their gastrointestinal cancers (OR = 1.31;
95% CI = 0.80-2.16). The P for trend estimated from
Cochran-Armitage trend test over the three ordered
groups: “no family history”, “having a family history of
late-onset gastrointestinal cancer”, and “having a family
history of early-onset gastrointestinal cancer” was 0.057.
When family history of gastrointestinal cancers was ana-
lyzed separately by tumor site, risk of DGA was increased
among individuals with a family history of gastric cancer
(OR = 2.15; 95% CI = 1.18-3.91), particularly early-onset
gastric cancer (OR = 2.82; 95% CI = 1.11-7.15; not shown
in the tables). Risk of DGA was also increased among
individuals with a family history of pancreatic cancer
(OR = 2.17; 95% CI = 0.72-6.51), even though the associ-
ation was not statistically significant. Further adjustments
for personal history of hiatal hernia, reflux symptoms, and
sibship size did not substantially change these associations
for EA, GCA, and DGA (data not shown).
We also investigated whether family history of gastro-
esophageal disorders including any ulcer, gastritis, hiatal
hernia, or Barrett’s esophagus was associated with risk of
adenocarcinomas at the three sites, with adjustment for
matching factors as well as other known risk factors of
these adenocarcinomas (Table 3). Results were similar
without adjustment for these other known risk factors
(Additional file 1: Table S2). Family history of Barrett’s
esophagus was rarely reported by the study participants.
Risk of EA was positively associated with a family history
of ulcers (OR = 1.49; 95% = 0.99-2.25) and a family his-
tory of hiatal hernia (OR = 2.04; 95% CI = 1.12-3.71).
Risk of GCA was also associated with a family history ofhiatal hernia (OR = 2.31; 95% CI = 1.37-3.91). There was
no significant association between family history of gas-
troesophageal disorders and risk of DGA.
Table 4 presents the combined effects of personal and
family history of hiatal hernia on risk of EA, GCA, and
DGA. Risk of EA was slightly elevated among individuals
with a family history of hiatal hernia but no personal
history of hiatal hernia (OR, 1.26; 95% CI, 0.52-3.08),
intermediate among those with a personal history of hia-
tal hernia but no family history of hiatal hernia (OR,
4.91; 95% CI, 3.04-7.93), and highest among individuals
with both a personal and a family history of hiatal hernia
(OR, 10.75; 95%, 4.26-27.12). Both personal and family
histories of hiatal hernia were associated with higher risk
of GCA; risk was also highest among individuals with a
personal and a family history of hiatal hernia. We also
included a product term in the regression model to test
for interaction between personal and family histories of
hiatal hernia for their effect on risk of EA and GCA,
and both interactions were not statistically significant
(P = 0.50 and 0.48 respectively). There was no association
between personal or family history of hiatal hernia and
risk of DGA (Table 4).
Discussion
In this large population-based case–control study, we
found site-specific associations between family history of
cancer or gastroesophageal disorders and risk of EA,
GCA, and DGA. Family history of cancer in the prostate
was associated with an increased risk of EA; family history
of esophageal cancer was associated with an increased
risk of GCA; and family history of gastrointestinal can-
cer and particularly gastric cancer was associated with
an increased risk of DGA. In addition, family history of
hiatal hernia was associated with an increased risk of
both EA and GCA, an effect that was more pronounced
among individuals with a personal history of hiatal hernia.




Controls Cases OR (95% CI)a Pa Cases OR (95% CI)a Pa Cases OR (95% CI)a Pa
Any ulcer
No 1010 108 1.00 (ref) 138 1.00 (ref) 223 1.00 (ref)
Yes 279 38 1.49 (0.99-2.25) 0.057 40 1.13 (0.77-1.66) 0.54 59 1.04 (0.74-1.47) 0.80
Gastritis
No 1168 134 1.00 (ref) 165 1.00 (ref) 257 1.00 (ref)
Yes 112 12 0.97 (0.51-1.87) 0.93 9 0.59 (0.29-1.21) 0.15 24 1.02 (0.62-1.67) 0.95
Hiatal hernia
No 1200 130 1.00 (ref) 153 1.00 (ref) 268 1.00 (ref)
Yes 80 16 2.04 (1.12-3.71) 0.020 22 2.31 (1.37-3.91) 0.002 10 0.90 (0.44-1.84) 0.77
Barrett’s esophagus
No 1272 141 1.00 (ref) 169 1.00 (ref) 259 1.00 (ref)
Yes 5 2 - - 0 - - 0 - -
Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardiac adenocarcinoma; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval.
aResults were estimated from multivariate polytomous logistic regression, with adjustment for age, sex, race, education, birth place, cigarette smoking status, body
mass index and history of diabetes. History of any ulcer, gastritis, hiatal hernia, and Barrett’s esophagus among first degree relatives was unknown for 28, 42, 44,
and 75 participants respectively.
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between family history of hiatal hernia and risk of EA
and GCA.
The rapid increase in the incidence of EA over the past
few decades in Western countries may indicate a strong
contribution of environmental factors to the etiology of EA
[21], but genetic factors may also play a role. To date, there
is a paucity of genetic association studies of EA [4]. Given
that Barrett’s esophagus is an established risk factor for EA
[22,23] and Barrett’s esophagus patients have a more than
30 times greater risk of developing EA [21], most previous
genetic studies compared patients with Barrett’s esophagus
and/or EA with controls and found evidence of familial
aggregation of these conditions [4]. It has been suggested
that polymorphisms in genes involved in the detoxification
of xenobiotics and luminal toxic agents (e.g. GSTM1,
GSTT1, GSTP1) as well as those involved in the regula-
tion of cell cycle progression (e.g. CCND1) may play a
role in individual susceptibility to EA [4]. Recently, a






Controls Cases OR (95% CI)a
No No 1117 93 1.00 (ref)
No Yes 68 6 1.26 (0.52-3.08)
Yes No 82 36 4.91 (3.04-7.93)
Yes Yes 12 10 10.75 (4.26-27.12)
P for interaction=
Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardiac adenocarcinom
aResults were estimated from multivariate polytomous logistic regression, with adju
mass index and history of diabetes.[24] has identified two susceptibility loci on chromosomes
16q24 and 6p21. The closest protein-coding gene to
the 16q24 locus is FOXF1, a gene implicated in esopha-
geal development and structure. This finding suggests
that structural factors related to the development of the
esophagus may play a role in the etiology of Barrett’s
esophagus. It is consistent with the fact that most of indi-
viduals affected by Barrett’s esophagus have a history of
hiatal hernia in their lower esophagus. We found that EA
risk was higher among individuals with a family history of
hiatal hernia (OR = 2.05) than those without this history
and that risk is highest among those with both a personal
and a family history of hiatal hernia (OR = 10.75). The
observation that EA risk increases with an increasing
number of family members (participant’s family plus
participant him/herself ) affected by hiatal hernia suggests
that genetic factors that are involved in the development
of hiatal hernia and Barrett’s esophagus play a role in the
development of EA. In addition, even though in our study
personal and family history of hiatal hernia was obtainedof esophageal and gastric adenocarcinoma
GCA DGA
Pa Cases OR (95% CI)a Pa Cases OR (95% CI)a Pa
129 1.00 (ref) 249 1.00 (ref)
0.61 13 1.89 (0.99-3.61) 0.056 8 0.89 (0.40-1.97) 0.77
<0.001 23 2.36 (1.40-3.97) 0.001 17 1.44 (0.80-2.60) 0.22
<0.001 9 6.55 (2.60-16.50) <0.001 2 - -
0.50 0.48 0.99
a; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval.
stment for age, sex, race, education, birth place, cigarette smoking status, body
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strong evidence of familial aggregation of Barrett’s
esophagus and EA from previous studies [4,25,26], in
which patients were ascertained through clinical diagnosis.
We also found an increased risk of EA among individ-
uals with a family history of prostate cancer but lower
risk among those with a family history of breast cancer
and these associations did not substantially change after
controlling for gender-specific sibship size. Such results
were unexpected and require confirmation. Reports of
associations between family history of breast or prostate
cancer and risk of gastroesophageal cancer are sparse
and have been inconsistent [11,12,14]. A multicenter,
population-based case–control study conducted in the
U.S. during 1993-1995 [12] found that family history of
breast cancer was associated with increased risks of EA
and non-cardia gastric adenocarcinoma, while the asso-
ciation of family history of prostate cancer with lower
risk of these two types of cancers was not statistically
significant. In a case–control study of patients seen at
the Memorial Sloan-Kettering Cancer Center from 1992
to 1994, family history of breast or prostate cancer was
not associated with an increased risk of EA and GCA
[11]. In a study based on the Swedish Family-Cancer
Database [14], maternal breast cancer was associated
with an increased risk of gastric cancer in the offspring
(standardized incidence ratio = 1.84, 95% CI = 1.02-3.04).
Despite these sparse observations, our results are consist-
ent with the strong male dominance in EA [27]. Among
white Americans, males have 7.7 times higher risk of
getting EA than females [28]. In addition, this gender
difference cannot be adequately explained by differences
in known risk factors for EA including gastroesphageal
reflux diseases, obesity, and tobacco consumption [29],
suggesting that other unknown factors such as sex hormo-
nal factors and related signaling axes may play important
roles in the development of EA [27,29]. Experimental
studies have shown that estrogen may have an inhibitory
effect [27] and androgens may have growth-enhancing
effects [30] on the carcinogenic process of the esophagus.
Compared to individuals without a family history of pros-
tate cancer, those with a positive family history may have a
higher exposure to androgens [31] or enhanced suscepti-
bility to the effect of androgens, leading to a higher risk
of esophageal cancer. Similarly, individuals with a fam-
ily history of breast cancer may have higher exposure
to estrogen [32] or enhanced susceptibility to the effect
of estrogen, therefore resulting in a reduced risk of
esophageal cancer.
EA and GCA display some similar descriptive epidemio-
logical features [1] and risk factors. Low intake of fiber
[19], hiatal hernia, and Barrett’s esophagus [17,22,23]
all have been associated with increased risks of both
EA and GCA. Therefore, it is not surprising that familyhistory of esophageal cancer was associated with an
increased risk of GCA, which might be explained by
common family dietary habits such as low fiber intake,
or by a shared genetic susceptibility to hiatal hernia and
Barrett’s esophagus. In the current study, additional ad-
justment for fiber intake did not explain the association
between family history of esophageal cancer and risk of
GCA, suggesting that shared genetic susceptibility may
play a more important role.
The observed association between family history of a
gastrointestinal cancer or of gastric cancer and an increased
risk of DGA could be explained by shared susceptibility
to both genetic and environmental factors. Family studies
[33,34] have shown that shared and non-shared environ-
mental factors largely accounted for the variation in
gastric cancer whereas genetic factors accounted for
only a small proportion of gastric cancer susceptibility.
This observation is consistent with the sharp decline in
gastric cancer incidence over the past 40 years, owing
to improvements in diet and food storage methods as
well as a decline in the prevalence of H. pylori infection
[35]. Common exposure to H. pylori may explain the
positive associations of GCA risk with family history of
gastric cancer and family history of other gastrointestinal
cancers, as H. pylori infection has been shown to increase
the risk of not only gastric cancer, but also pancreatic can-
cer [36]. Data on history of H. pylori infection was not
available for majority of our study participants; therefore
we were unable to investigate whether history of H. pylori
infection was a potential effect modifier of the association
between family history of gastric cancer and risk of GCA.
However, the associations between family history of these
gastrointestinal cancers and increased risk of GCA may
also be mediated by shared genetic susceptibilities [37].
For example, candidate gene studies have consistently
found that polymorphisms in the IL-1β and MTHFR
genes were associated with individual susceptibility
to both intestinal-type gastric cancer and pancreatic
cancer [4,38,39].
The strengths of this study include the population-based
design, relatively large sample size, separation of gastro-
esophageal adenocarcinoma by anatomical sites, and data
on family history of cancer and non-malignant gastro-
esophageal disorders. Results from our study are com-
patible with the limited evidence to date and known
etiological mechanisms of EA, GCA, and DGA. Our study
also has a number of limitations. First, even though we
excluded NOK interview data from our analyses, our data
on family history were reported by study participants
rather than by family member themselves; therefore
they may be subject to recall bias, under-ascertainment
of family history, and misclassification of the primary
tumor site. The lack of excessive reporting of family
history of esophageal cancer by cases with EA indicates
Jiang et al. BMC Cancer 2014, 14:60 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/60that our results were most likely not affected by selective
recall bias. In addition, misclassification of the primary
tumor site of a relative was lessened by only collecting
data on first-degree relatives [40]. Nevertheless, it is not
possible to collect information on histology (e.g. adenocar-
cinoma vs. squamous cell carcinoma) or specific tumor
subsite (gastric cardia vs. non-cardia) among those who
reported esophageal/gastric cancers in first-degree rela-
tives. Second, our sample size was insufficient to evaluate
very rare cancers in family members, to examine risk
patterns separately for parents vs. siblings or to assess
whether the number of affected relatives refined risk
estimates. In particular, there was only one EA patient
and seven controls with a positive family history of EA,
our study was not sufficient powered to examine the
association between family history of EA and risk of EA.
However, sparse-data bias was unlikely to have occurred,
because: a) reducing over-stratification in our regression
analyses, i.e. removing additional adjustment for known
risk factors (Additional file 1: Tables S1 and S2 versus
Tables 2 and 3), did not change our results substantially;
and b) our results were very similar with and without
Firth’s correction [41] for sparse data (data not shown). A
pooled analysis of data from all relevant population-based
studies is needed for these additional analyses. Third,
we recognize that if the effect of family history of cancer
or gastroesophageal disorders may be exerted through
common family dietary habits or by a shared genetic
susceptibility, adjusting for known risk factors for gas-
troesophageal cancer may underestimate the actual
strength of the association between family history of
cancer/gastroesophageal disorders and risk of gastro-
esophageal cancer. However, overadjustment is unlikely
because, as mentioned above, removing additional ad-
justment for known risk factors did not change our re-
sults substantially. Fourth, BMI was categorized using
sex-specific quartiles rather than the World Health
Organization classification to avoid sparse data for some
categories. In addition, we did not control for history of
Helicobacter pylori (H. pylori) infection in multivariate
analyses, because serum IgG antibodies to H. pylori
whole-cell antigens (Helico-G) and CagA were not mea-
sured for majority of study participants [16]. Furthermore,
we were unable to distinguish shared genetics from shared
early-life environmental exposures among first-degree rel-
atives, as environmental exposure histories of participants’
relatives were not available.
Conclusions
In summary, our data suggest that family history of can-
cers at specific sites may be associated with risk of EA,
GCA, and DGA. These associations may be mediated by
shared environmental factors as well as by genetic factors.
Our limited sample size warrants cautious interpretationof the observed null associations. Pooled analyses of indi-
vidual studies are required for more precise quantification
and more thorough investigation of the associations of
family history of cancer or gastroesophageal disorders with
the development of EA, GCA, and DGA.
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